HTEP working group looks at dossier requirements
This article was originally published in Clinica
The European Medicines Agency's Working Party on Cell-Based Products (CPWP) is holding the first of five meetings scheduled for 2008 on February 14-15. Among its regulatory activities are the development of technical dossier requirements for human tissue-engineered products. The deadline is the second quarter of this year.
You may also be interested in...
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.